The DOI matches its OpenAlex record; 47 of the 47 references it cites were found in a registry or an index.
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Abstract
This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 6,094
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
New Tables for Multiple Comparisons with a Control
Dunnett, C. W. (1964) · Biometrics · doi:10.2307/2528490 · Cited by 3,113
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Cited by
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884
Self-citationGoldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 594
Oral antihyperglycemic therapy for type 2 diabetes mellitus
Cheng, A. Y. Y. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031414 · Cited by 502
The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones
ARNER, P. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(03)00024-9 · Cited by 423
The mode of action of thiazolidinediones
Hauner, H. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.249 · Cited by 411
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1876-2 · Cited by 376
Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Raskin, P., Rendell, M., Riddle, M. C., Dole, J. F., Freed, M. I., Rosenstock, J., & For the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1226 · Cited by 345
Self-citationChemistry and Biochemistry of Type 2 Diabetes
Ross, S. A., Gulve, E. A., & Wang, M. (2004) · Chemical Reviews · doi:10.1021/cr0204653 · Cited by 323
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Phillips, L. S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E. B., Salzman, A., & the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.2.308 · Cited by 302
Self-citationThe evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes
Bergman, R. N., Finegood, D. T., & Kahn, S. E. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.5.x · Cited by 301
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Chiquette, E., Ramirez, G., & DeFronzo, R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2097 · Cited by 291
Greenberg, A. S., & McDaniel, M. L. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.4.x · Cited by 290
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
De Leo, V., la Marca, A., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 286
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
A Diabetes Outcome Progression Trial (ADOPT)
Viberti, G., Kahn, S. E., Greene, D. A., Herman, W. H., Zinman, B., Holman, R. R., Haffner, S. M., Levy, D., Lachin, J. M., Berry, R. A., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1737 · Cited by 273
Self-citationComparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes
Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., & Schweizer, A. (2007) · Diabetes Care · doi:10.2337/dc06-1815 · Cited by 270
St. John Sutton, M., Rendell, M., Dandona, P., Dole, J. F., Murphy, K., Patwardhan, R., Patel, J., Freed, M., & For the Rosiglitazone Clinical Trials Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2058 · Cited by 254
Self-citationInsulin signaling and glucose transport in insulin resistant human skeletal muscle
Karlsson, H. K. R., & Zierath, J. R. (2007) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-007-0030-9 · Cited by 159
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Nesto, R. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01296.x · Cited by 140
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Diani, A. R., Sawada, G., Wyse, B., Murray, F. T., & Khan, M. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00331.2003 · Cited by 100
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Bailey, C. J., Bagdonas, A., Rubes, J., McMorn, S. O., Donaldson, J., Biswas, N., & Stewart, M. W. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.012 · Cited by 73
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
Monnier, L., Benichou, M., Charra-Ebrard, S., Boegner, C., & Colette, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70174-x · Cited by 69
Kim, Y. M., Cha, B. S., Kim, D. J., Choi, S. H., Kim, S. K., Ahn, C. W., Lim, S.-K., Kim, K. R., Huh, K. B., & Lee, H. C. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.05.001 · Cited by 43
Cardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents
Granberry, M. C., & Fonseca, V. A. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00006 · Cited by 38
Metadata
- Authors
- Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- Oxford University Press
- Published
- 2001-01-01
- Volume
- 86
- Issue
- 1
- Pages
- 280-288
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2056726092
- Cited by
- 518
- References
- 47
- FWCI
- 33.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.